United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,827,875.04. The trade was a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Up 2.2%

UTHR opened at $527.91 on Friday. The company has a market capitalization of $22.64 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The firm has a 50-day simple moving average of $530.89 and a two-hundred day simple moving average of $538.86. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the firm posted $6.41 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada reduced their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. increased their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Callan Family Office LLC bought a new stake in shares of United Therapeutics during the second quarter worth $1,217,000. Leuthold Group LLC boosted its stake in shares of United Therapeutics by 41.4% during the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the period. UBS Group AG grew its holdings in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP grew its holdings in shares of United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after purchasing an additional 3,766 shares during the last quarter. Finally, M&T Bank Corp increased its stake in United Therapeutics by 171.6% in the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after buying an additional 1,985 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.